ATE120235T1 - Suppression von zell-proliferation durch decorin. - Google Patents

Suppression von zell-proliferation durch decorin.

Info

Publication number
ATE120235T1
ATE120235T1 AT89730152T AT89730152T ATE120235T1 AT E120235 T1 ATE120235 T1 AT E120235T1 AT 89730152 T AT89730152 T AT 89730152T AT 89730152 T AT89730152 T AT 89730152T AT E120235 T1 ATE120235 T1 AT E120235T1
Authority
AT
Austria
Prior art keywords
decorin
cell proliferation
suppression
suppress
proliferation
Prior art date
Application number
AT89730152T
Other languages
English (en)
Inventor
Erkki I Ruoslahti
Yu Yamaguchi
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Application granted granted Critical
Publication of ATE120235T1 publication Critical patent/ATE120235T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AT89730152T 1988-06-28 1989-06-24 Suppression von zell-proliferation durch decorin. ATE120235T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21270288A 1988-06-28 1988-06-28

Publications (1)

Publication Number Publication Date
ATE120235T1 true ATE120235T1 (de) 1995-04-15

Family

ID=22792114

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89730152T ATE120235T1 (de) 1988-06-28 1989-06-24 Suppression von zell-proliferation durch decorin.

Country Status (11)

Country Link
US (2) US5726149A (de)
EP (1) EP0349480B1 (de)
JP (3) JP2887325B2 (de)
AT (1) ATE120235T1 (de)
AU (1) AU633011B2 (de)
CA (1) CA1340112C (de)
DE (1) DE68921803T2 (de)
DK (1) DK306890A (de)
ES (1) ES2070926T3 (de)
FI (1) FI906411A7 (de)
WO (1) WO1990000194A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509314B1 (en) * 1988-06-28 2003-01-21 The Burnham Institute Methods of preventing or reducing scarring with decorin or biglycan
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
DE69232946T2 (de) * 1991-11-14 2003-12-18 La Jolla Cancer Research Foundation, La Jolla Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung
US5830847A (en) * 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
US5650389A (en) * 1993-03-01 1997-07-22 University Of Alabama At Birmingham Research Foundation Methods for the inhibition of complement activation
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
ZA946595B (en) * 1993-09-03 1996-02-28 Res Dev Foundation Mutants of the retinoblastoma and P53 genes and uses thereof
US5567807A (en) * 1994-07-08 1996-10-22 La Jolla Cancer Research Foundation Processes for the purification of human recombinant decorin and the detection of guanidinium ions
JP2001520877A (ja) 1997-10-28 2001-11-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 血管平滑筋細胞のインビトロ分化、それに関する方法および試薬
WO2001085192A1 (en) * 2000-05-05 2001-11-15 Gtc Biotherapeutics, Inc. Transgenically produced decorin
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
CA2472882A1 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
BRPI0307070A2 (pt) * 2002-01-22 2019-03-26 Genzyme Corporation uso de antagonistas tgf-beta para tratar ou prevenir rejeição crônica de transplante
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
JP5481028B2 (ja) * 2004-10-13 2014-04-23 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ウイルス関連リンパ増殖性障害を処置または予防するための方法
KR100747646B1 (ko) * 2005-02-25 2007-08-08 연세대학교 산학협력단 데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
JP2006295872A (ja) * 2005-03-18 2006-10-26 Matsushita Electric Ind Co Ltd 機器固有鍵の生成方法、これを用いた機密情報処理機能を備えた機密情報ｌｓｉ、これを搭載したホスト機器、これに用いられる認証機能付き記録媒体、および認証機能を備えた記録媒体付き携帯端末
US8293900B2 (en) 2005-09-29 2012-10-23 Merck Sharp & Dohme Corp Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
EP1998810A4 (de) 2006-03-13 2009-09-02 Univ Johns Hopkins Erhöhung der endothelialen thromboresistenz
EP2698157B1 (de) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
PL2918288T3 (pl) 2006-10-03 2018-02-28 Genzyme Corporation Zastosowanie antagonistów TGF beta do leczenia niemowląt obarczonych ryzykiem rozwinięcia dysplazji oskrzelowo-płucnej
US9053063B2 (en) 2007-02-21 2015-06-09 At&T Intellectual Property I, Lp Method and apparatus for authenticating a communication device
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
US8911736B2 (en) 2010-03-12 2014-12-16 Genzyme Corporation Combination therapy for treating breast cancer
KR20130131414A (ko) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 ｉＰＳ 세포와 그 제조법
US20120238727A1 (en) * 2011-03-14 2012-09-20 Catalent Pharma Solutions Llc Decorin compositions and use thereof
WO2013014262A1 (en) 2011-07-27 2013-01-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating myhre syndrome
CA2853484C (en) 2011-10-26 2018-08-21 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2917222T3 (es) 2011-12-28 2022-07-07 Kyoto Prefectural Public Univ Corp Normalización del cultivo de células endoteliales de la córnea
CA2907944C (en) 2013-04-22 2020-11-03 Catalent Pharma Solutions, Llc Veterinary decorin compositions and use thereof
CA2927898C (en) 2013-10-31 2021-11-16 Kyoto Prefectural Public University Corporation Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium
WO2016187312A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection
JP7736572B2 (ja) * 2019-06-06 2025-09-09 アロア・バイオサージェリー・リミテッド 生物活性剤及びそれに関連した方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI945466A0 (fi) * 1987-03-23 1994-11-21 Amgen Inc Verihiutaleista peräisin olevaa kasvutekijää tuottavia solulinjoja
US5583103A (en) * 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity

Also Published As

Publication number Publication date
US5726149A (en) 1998-03-10
FI906411A0 (fi) 1990-12-27
AU3865389A (en) 1990-01-23
DE68921803D1 (de) 1995-04-27
FI906411A7 (fi) 1990-12-27
WO1990000194A1 (en) 1990-01-11
JP2887325B2 (ja) 1999-04-26
JP2003034651A (ja) 2003-02-07
DK306890D0 (da) 1990-12-28
DK306890A (da) 1990-12-28
EP0349480B1 (de) 1995-03-22
JPH09117278A (ja) 1997-05-06
ES2070926T3 (es) 1995-06-16
AU633011B2 (en) 1993-01-21
EP0349480A1 (de) 1990-01-03
CA1340112C (en) 1998-11-03
DE68921803T2 (de) 1995-07-13
JPH03503846A (ja) 1991-08-29
US6046162A (en) 2000-04-04

Similar Documents

Publication Publication Date Title
ATE120235T1 (de) Suppression von zell-proliferation durch decorin.
EP0123811A3 (en) The use of the gal 1 yeast promoter
DE69032406D1 (de) Wundheilmittel enthaltend heparanase
AU542834B2 (en) Anti-invasion factor containing cultures
AU543292B2 (en) Hydrocracking with separation of recycle hydrogen by membrane
ES2036192T3 (es) Derivados del acido (met)-acrilico, que contienen grupos uretano, de triciclo (5.2.1.0.2.6) decano.
EP0113328A3 (en) Static cell culture maintenance system
GB8418775D0 (en) Operation of microbial fuel cells
EP0305275A3 (de) Pflanzen, die mit einer DNS-Sequenz aus Bacillus thuringiensis transformiert werden
DE3578923D1 (de) Verwendung von aryloxy-verbindungen als antidots.
AU621245B2 (en) Hydrolase substrates, a process for the preparation thereof and agents containing them
ATE76660T1 (de) Enzyme fuer den abbau von lignin.
DK359487D0 (da) Fremgangsmaade til udvirkning af foroeget ekspression af rekombinant faktor viii i en vaertscelle
ZA917561B (en) Media for culture of mammalian cells
AU617059B2 (en) Monosulfactams
AU3857185A (en) Cell culturing with gas sparging
NO905610L (no) Undertrykkelse av celleproliferasjon ved hjelp av decorin.
AU2928284A (en) Replacement of damaged membranes in electrolytic cells
IT8521051V0 (it) Formatore di pozzetti.
DE69104357D1 (de) Klonierungs- und/oder expressionsvektoren, verfahren zur ihrer herstellung und verwendung.
DE3481778D1 (de) Verwendung von vernetzerkombinationen enthaltende polyurethanzubereitungen als thermoaktive haftstriche.
CA2133345A1 (en) A Method of Limiting the Survival of Genetically Engineered Microorganisms in Their Environment
AU524884B2 (en) Refining high carbon steel
AU561330B2 (en) Liquefaction of coal with hydrogen
AU4986585A (en) Arched storage shed with external framework/internal cladding

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee